Anika Therapeutics, Inc. Stock price

Equities

ANIK

US0352551081

Pharmaceuticals

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
25.4 USD -0.55% Intraday chart for Anika Therapeutics, Inc. +0.04% +12.09%
Sales 2024 * 170M Sales 2025 * 182M Capitalization 372M
Net income 2024 * -2M Net income 2025 * 6M EV / Sales 2024 * 2.19 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.05 x
P/E ratio 2024 *
-166 x
P/E ratio 2025 *
61.5 x
Employees 357
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.4%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.55%
1 week+0.04%
Current month+4.61%
1 month+2.54%
3 months+12.19%
6 months+34.53%
Current year+12.09%
More quotes
1 week
25.00
Extreme 25
25.73
1 month
21.00
Extreme 21
27.31
Current year
21.00
Extreme 21
27.31
1 year
16.54
Extreme 16.54
29.26
3 years
16.54
Extreme 16.54
48.37
5 years
16.54
Extreme 16.54
75.72
10 years
16.54
Extreme 16.54
75.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 18-08-30
Director of Finance/CFO 50 20-08-09
Chief Operating Officer 55 21-08-31
Members of the board TitleAgeSince
Director/Board Member 70 18-10-22
Director/Board Member 63 21-10-27
Chief Executive Officer 59 18-08-30
More insiders
Date Price Change Volume
24-03-28 25.4 -0.55% 83,692
24-03-27 25.54 +0.71% 57,868
24-03-26 25.36 +1.08% 55,020
24-03-25 25.09 -1.45% 141,102
24-03-22 25.46 +0.28% 83,961

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
25.4 USD
Average target price
30.33 USD
Spread / Average Target
+19.42%
Consensus
  1. Stock
  2. Equities
  3. Stock Anika Therapeutics, Inc. - Nasdaq